Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 7/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145186 | 0.99 | BDKRB1 (0.67) | BDKRB1KCNH2L3MBTL1RXFP1DRD2 | |
| SCHEMBL3280606 | 0.87 | BDKRB1 (0.62) | BDKRB1KCNH2ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL15103785 | 0.86 | BDKRB1 (0.61) | BDKRB1KCNH2L3MBTL1RXFP1ALDH1A1 | |
| SCHEMBL3144805 | 0.86 | BDKRB1 (0.50) | BDKRB1KCNH2L3MBTL1RXFP1 | |
| SCHEMBL3149723 | 0.85 | BDKRB1 (0.51) | BDKRB1KCNH2L3MBTL1RXFP1 | |
| SCHEMBL3273902 | 0.83 | BDKRB1 (0.59) | BDKRB1KCNH2L3MBTL1ALDH1A1PKM | |
| SCHEMBL5101094 | 0.79 | BDKRB1 (1.00) | BDKRB1KCNH2ALDH1A1PKM | |
| SCHEMBL3280590 | 0.77 | BDKRB1 (0.53) | BDKRB1KCNH2ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL3139038 | 0.77 | ITGB3 (0.50) | BDKRB1KCNH2L3MBTL1RXFP1 | |
| SCHEMBL3147694 | 0.77 | BDKRB1 (0.61) | BDKRB1KCNH2DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | BDKRB1 1/4885KCNH2 80/4885L3MBTL1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.